Cue Health

Cue Health, Inc. is a healthcare technology company that puts consumers in control of their health information and places diagnostic information at the center of care. It enables people to manage their health through real-time, actionable, and connected health information, offering individuals and their healthcare providers easy access to lab-quality diagnostics anywhere, anytime, in a device that fits in the palm of the hand. The firms first-of-its-kind COVID-19 test was the first FDA-authorized molecular diagnostic test for at-home and over-the-counter use without a prescription and physician supervision. The company was founded by Ayub Khattak and Clint Sever in 2010 and is headquartered in San Diego, CA.

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Nobilis Health Corp. engages in the operation and development of outpatient surgery centers. The firm owns and manages ambulatory and acute care facilities to deliver innovative surgical services. It operates through Medical Services and Marketing Services segment. The Medical Services segment provides the operation of hospitals, outpatient facilities, and other various related health care services. The Marketing Services segment provides marketing services, patient education services, and patient care coordination management services. The company was founded on March 16, 2007 and is headquartered in Houston, TX.

SAN DIEGO, Calif.--(BUSINESS WIRE)--Cue Health Inc. (“Cue”) (Nasdaq: HLTH), a healthcare technology company, announced today that it will release its second quarter 2023 financial results on Wednesday, August 9, 2023. In conjunction with the release, Cue will host a conference call and webcast that day at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time to discuss its financial results and recent highlights. To access the live call via telephone, please register in advance using the link here. U.

Cue Health to Announce Second Quarter 2023 Financial Results

SAN DIEGO--(BUSINESS WIRE)--Cue Health (Nasdaq: HLTH), a healthcare technology company, announces an industry breakthrough as the first company to receive De Novo authorization from the U.S. Food and Drug Administration (FDA) for its Cue COVID-19 Molecular Test, designed for both home and point-of-care use. This sets a new standard as the first FDA De Novo authorization for a home use COVID-19 test and the first De Novo granted for any home use respiratory test. This significant achievement hig.

Cue Health Achieves Groundbreaking Milestone with FDA: First Company to Receive De Novo Authorization for a COVID-19 Home Use Test

The U.S. Food and Drug Administration on Tuesday approved Cue Health's at-home COVID-19 test, the first coronavirus test to get marketing authorization using a traditional premarket review, the agency said.

US FDA approves Cue Health's at-home COVID test

SAN DIEGO, Calif.--(BUSINESS WIRE)--Cue Health (“Cue”) (Nasdaq: HLTH), a healthcare technology company, announced today that its management team will present at the Goldman Sachs 44th Annual Global Healthcare Conference on Wednesday, June 14, 2023 at 4:00 p.m. Pacific Time at the Waldorf Astoria Monarch Beach Resort & Club. A live audio webcast and replay of the presentation may be accessed for 180 days on the “Investor Relations” section of the company's website at: https://cuehealth.com/.

Cue Health to Present at the Goldman Sachs 44th Annual Global Healthcare Conference

Cue Health Inc. (HLTH) appears to have found support after losing some value lately, as indicated by the formation of a hammer chart. In addition to this technical chart pattern, strong agreement among Wall Street analysts in revising earnings estimates higher enhances the stock's potential for a turnaround in the near term.

Cue Health Inc. (HLTH) Forms 'Hammer Chart Pattern': Time for Bottom Fishing?

Cue Health Inc. (HLTH) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

Cue Health Inc. (HLTH) Upgraded to Buy: Here's What You Should Know

Cue Health Inc. (HLTH) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.

Cue Health Inc. (HLTH) Loses -47.82% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner

Cue Health, Inc. (NASDAQ:HLTH ) Q1 2023 Earnings Conference Call May 10, 2023 4:30 PM ET Company Participants Lorna Williams - IR Ayub Khattak - Co-Founder, President, CEO & Chairman Aasim Javed - CFO Conference Call Participants Gaby Teran - Morgan Stanley Dave Delahunt - Goldman Sachs Operator Good day and thank you for standing by and welcome to the Cue Health First Quarter 2023 Earnings Call. At this time, all participants are in a listen-only mode.

Cue Health, Inc. (HLTH) Q1 2023 Earnings Call Transcript

SAN DIEGO--(BUSINESS WIRE)--Cue Health Inc. ("Cue") (Nasdaq: HLTH), a healthcare technology company, today reported financial results for the first quarter 2023. Recent Highlights Reported first quarter revenue of $24.8 million Granted U.S. Food and Drug Administration (FDA) Emergency Use Authorization (EUA) for Cue Mpox (Monkeypox) Molecular Test for point-of-care use Submitted the Cue RSV Molecular Test as a De Novo submission to the FDA for home and point-of-care use during the second quarte.

Cue Health Reports First Quarter 2023 Financial Results

SAN DIEGO--(BUSINESS WIRE)--Cue Health (“Cue”) (Nasdaq: HLTH), a healthcare technology company, today announced that it has made a De Novo submission to the U.S. Food and Drug Administration (FDA) for full clearance of the Cue RSV Molecular Test for at-home and point-of-care use. There are currently no respiratory syncytial virus (RSV) tests on the market for home use. Pending FDA clearance, Cue's test would provide the public, for the first time, an at-home molecular RSV test to use on people.

Cue Health Makes De Novo Submission to FDA for Full Clearance of its Cue® RSV Molecular Test

SAN DIEGO--(BUSINESS WIRE)--Cue Health (“Cue”) (Nasdaq: HLTH), a healthcare technology company, today announced an expansion of its Cue Integrated Care Platform to include a new pharmacy offering with over-the-counter and prescription medication options for a growing number of common health and wellness needs. These include sexual health - such as erectile dysfunction and herpes - as well as birth control, hair loss, and more. Building on last month's launch of its new collection of consumer-fr.

Cue Health Launches Pharmacy Offering to Empower Individuals to Manage Common Health and Wellness Needs from Home

SAN DIEGO--(BUSINESS WIRE)--Cue Health Inc. (“Cue”) (Nasdaq: HLTH), a healthcare technology company, announced today that it will release its first quarter 2023 financial results on Wednesday, May 10, 2023. In conjunction with the release, Cue will host a conference call and webcast that day at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time to discuss its financial results and recent highlights. To access the live call via telephone, please register in advance using the link here. Upon registe.

Cue Health to Announce First Quarter 2023 Financial Results

LOS ANGELES, CA / ACCESSWIRE / April 26, 2023 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Cue Health Inc. ("Cue Health" or "the Company") (NASDAQ:HLTH) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.

SHAREHOLDER ACTION NOTICE: The Schall Law Firm Announces it is Investigating Claims Against Cue Health Inc. and Encourages Investors with Losses to Contact the Firm

LOS ANGELES--(BUSINESS WIRE)---- $HLTH #HLTH--The Schall Law Firm Announces it is Investigating Claims Against Cue Health Inc. and Encourages Investors with Losses to Contact the Firm.

INVESTIGATION REMINDER: The Schall Law Firm Announces it is Investigating Claims Against Cue Health Inc. and Encourages Investors with Losses to Contact the Firm

INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Cue Health Inc. and Encourages Investors with Losses to Contact the Firm

SAN DIEGO--(BUSINESS WIRE)--Cue Health (“Cue”) (Nasdaq: HLTH), a healthcare technology company, today announced it has received Emergency Use Authorization (EUA) from the United States Food and Drug Administration (FDA) for its molecular test to detect the mpox virus (formerly known as monkeypox).

Cue Health Receives FDA Emergency Use Authorization for Molecular Mpox Test

Cue Health, Inc. (NASDAQ:HLTH ) Q4 2022 Earnings Conference Call March 15, 2023 4:30 PM ET Company Participants Lorna Williams - IR Ayub Khattak - Co-Founder, President, CEO & Chairman Aasim Javed - CFO Conference Call Participants Tejas Savant - Morgan Stanley. Matthew Sykes - Goldman Sachs Mark Massaro - BTIG Operator Good day, and thank you for standing by.

Cue Health, Inc. (HLTH) Q4 2022 Earnings Call Transcript

SAN DIEGO--(BUSINESS WIRE)--Cue Health Inc. ("Cue") (Nasdaq: HLTH), a healthcare technology company, today reported financial results for the fourth quarter and full-year 2022. Recent and Full-Year 2022 Highlights Reported fourth quarter revenue of $146.8 million, including $92.4 million in deferred revenue related to our agreement with the U.S. Department of Defense. Full-year 2022 revenue was $483.5 million.

Cue Health Reports Fourth Quarter and Full-Year 2022 Financial Results

SAN DIEGO--(BUSINESS WIRE)--Cue Health (“Cue”) (Nasdaq: HLTH), a healthcare technology company, today announced the nationwide launch of a new suite of consumer-friendly, at-home diagnostic test kits. These easy-to-use kits provide individuals with access to accurate, reliable testing from the comfort of their own homes, making it easier for people to take control of their health. The tests are integrated into Cue Care – the company's innovative test-to-treat service.

Cue Health's New Suite of At-Home Diagnostic Tests and Expansion of Cue Care Puts You in Control of Your Health

SAN DIEGO--(BUSINESS WIRE)--Cue Health (“Cue”) (Nasdaq: HLTH), the healthcare technology leader in at-home and point-of-care diagnostic innovations, today announced a new collaboration with Pfizer Inc. in the U.S. to raise awareness among individuals with certain underlying conditions about the risks of progressing to severe COVID-19 and the importance of seeking treatment if they test positive.

Cue Health Collaborates with Pfizer to Provide People who Test Positive for COVID-19 with Actionable Health Information to Better Inform their Treatment Journey

SAN DIEGO--(BUSINESS WIRE)--Cue Health Inc. (“Cue”) (Nasdaq: HLTH), a healthcare technology company, announced today that it will release its fourth quarter and full-year 2022 financial results on Wednesday, March 15, 2023. In conjunction with the release, Cue will host a conference call and webcast that day at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time to discuss its financial results and recent highlights.

Cue Health to Announce Fourth Quarter and Full-Year 2022 Financial Results

SAN DIEGO--( BUSINESS WIRE )--Cue Health (“Cue”) (Nasdaq: HLTH), the healthcare technology company known for diagnostic enabled care, announced today that its management team will participate at the following investor conferences:

Cue Health to Participate at Upcoming Investor Conferences

SAN DIEGO--( BUSINESS WIRE )--Cue Health (“Cue”) (Nasdaq: HLTH), the healthcare technology company known for diagnostic enabled care, today announced that it has been selected by Minnesota Department of Health (MDH) to provide a statewide COVID-19 telehealth to treatment program, powered by Cue Care™, at no cost to Minnesota residents.

Cue Health Selected by Minnesota Department of Health to Provide Statewide Telehealth to Treatment Services to all Minnesota Residents at No Cost

SAN DIEGO--( BUSINESS WIRE )--Cue Health (“Cue”) (Nasdaq: HLTH), a healthcare technology company that puts diagnostic information at the center of care, today announced that Josh Ghaim, Ph.D. and Sachin Jain, M.D. have joined its Board of Directors. Cue Health's Board now consists of seven directors, five of whom are independent.

Cue Health Announces Appointment of Josh Ghaim, Ph.D. and Sachin Jain, M.D.

Cue Health, Inc. (NASDAQ:HLTH ) Q3 2022 Earnings Conference Call November 9, 2022 4:30 PM ET Company Participants Lorna Williams - IR Ayub Khattak - Co-Founder, President, CEO & Chairman John Gallagher - CFO Conference Call Participants Neel Ram - Morgan Stanley David Delahunt - Goldman Sachs Mark Massaro - BTIG Steven Braun - Cowen Operator Good day, and thank you for standing by. Welcome to the Cue Health Third Quarter Earnings Conference Call.

News for Cue Health Stock (HLTH)